Clavicular's Retatrutide Protocol
Who is Braden Peters, why he chose retatrutide over semaglutide and tirzepatide, the clinical science behind each compound in his stack, and the ethics of influencer-driven peptide promotion.
Who Is Clavicular?
Clavicular, whose real name is Braden Peters, was born on December 17, 2005. He rose to prominence as a content creator on TikTok and Kick, where his streams covering fitness, peptides, and self-improvement attracted a rapidly growing audience. His open, unfiltered approach to discussing peptide use — including on-camera injections and detailed protocol breakdowns — differentiated him from the typical fitness influencer ecosystem.
Peters monetized his following through the "Clavicular System," a $50/month subscription course. The downstream effect on peptide culture was significant: search volume for "Retatrutide" among non-medical audiences increased substantially following his content, and BPC-157 became the most discussed healing peptide outside clinical settings.
- • February 2026 arrest: Peters was arrested in an incident that drew widespread media coverage and reignited debate about influencers promoting research peptides to young audiences.
- • On-stream injection of girlfriend: Generated significant backlash. Raised questions about informed consent and the normalization of injection practices to non-researchers.
- • These controversies have not diminished his audience — they amplified it. As of March 2026 he remains one of the most-discussed figures in online peptide communities.
Why Retatrutide Over Semaglutide or Tirzepatide?
Clavicular has stated repeatedly on stream that he chose retatrutide for one reason: maximum efficacy. The argument has scientific merit — each additional receptor target adds a distinct metabolic pathway.
| Compound | Receptor Targets | Max Weight Loss | Status |
|---|---|---|---|
| Semaglutide | GLP-1 only | -14.9% (STEP 1, 68 wks) | FDA-Approved |
| Tirzepatide | GIP + GLP-1 | -22.5% (SURMOUNT-1, 72 wks) | FDA-Approved |
| Retatrutide | GIP + GLP-1 + Glucagon | -28.7% (TRIUMPH-4, 68 wks) | Phase 3 |
The glucagon component adds thermogenesis, hepatic fat oxidation, and increased energy expenditure — mechanisms absent in semaglutide and tirzepatide.
The Clinical Science Behind Retatrutide
At 12 mg: 100% achieved ≥5% loss. 93% achieved ≥10%.
18.2% discontinuation at 12 mg — significantly higher than semaglutide (~5%) due to triple agonism GI burden.
The glucagon receptor component directly stimulates hepatic lipid oxidation — a mechanism absent in semaglutide and tirzepatide. This produced the largest liver fat reductions ever documented with any pharmacotherapy.
| Dose | Liver Fat Reduction |
|---|---|
| 1 mg | -42.9% |
| 4 mg | -57.0% |
| 8 mg | -81.4% |
| 12 mg | -82.4% |
| Placebo | +0.3% |
Shop Clavicular's Protocol
Research-grade Retatrutide and BPC-157 from Apollo Peptide Sciences — the exact peptides behind the most viral looksmaxxing transformation.
Why Combine BPC-157 with Retatrutide?
GLP-1 receptor agonists cause GI side effects in the majority of users. The gastroprotective rationale for adding BPC-157 is mechanistically grounded — even if no clinical trial has directly tested this combination.
- → Cytoprotection of gastric mucosa (Robert's cytoprotection model)
- → Acceleration of GI ulcer healing across multiple lesion models
- → Dual NO pathway modulation (VEGF-dependent + independent)
- → 36+ published studies from Dr. Predrag Sikiric (Univ. of Zagreb)
- → Stable in gastric juice for 24+ hours; no identified toxic dose
No clinical trial has evaluated BPC-157 + retatrutide co-administration. The mechanistic rationale is grounded in BPC-157's documented gastroprotective properties, but extrapolating preclinical results to human GLP-1 tolerability remains speculative.
Source Retatrutide for Research
Frequently Asked Questions
Clavicular has discussed various doses across different streams. He has generally indicated a preference for higher-end dosing consistent with the clinical trial range (up to 12 mg weekly), with gradual titration from lower starting doses. His exact current protocol has varied and is not independently verified.
No. As of March 2026, retatrutide is an investigational compound in Phase 3 clinical trials by Eli Lilly. The TRIUMPH Phase 3 program includes 5,800+ participants. The earliest possible FDA approval, if all trials succeed, would be 2027 or later.
Retatrutide produces substantially greater weight loss: -28.7% vs -14.9% in Phase 3/Phase 2 trials respectively. It engages three receptor systems (GIP, GLP-1, glucagon) vs semaglutide's single GLP-1 target. The glucagon component adds energy expenditure and thermogenesis. However, retatrutide has a higher adverse event profile (18.2% vs ~5% discontinuation rates) and is not FDA-approved.
No clinical trial has evaluated this combination. The rationale is based on BPC-157's documented gastroprotective properties in preclinical models. While the mechanistic logic is sound, there is no human safety or efficacy data for this specific combination.
Based on published data, retatrutide has produced the largest weight loss: -28.7% at 12 mg over 68 weeks in TRIUMPH-4 Phase 3. This exceeds tirzepatide (-22.5%) and semaglutide (-14.9%). However, retatrutide is investigational and not FDA-approved, while both tirzepatide (Zepbound) and semaglutide (Wegovy) are FDA-approved.
Build Clavicular's Stack
Research-grade Retatrutide + BPC-157 from Apollo Peptide Sciences. The exact protocol behind Clavicular's viral looksmaxxing transformation.